Recent Updates
Recently added Catalysts
WST Positive Sentiment

West Welcomes Robert McMahon as Incoming Chief Financial Officer

Key Takeaway: West Pharmaceutical Services has appointed Robert McMahon as its new Chief Financial Officer, effective August 4, 2025. McMahon, who has a strong background in finance and executive roles within the healthcare sector, will succeed Bernard Birkett, who is retiring. The company expresses confidence in McMahon's ability to drive financial success and support long-term growth.
Price reaction · baseline $210.89 (2025-07-18 close) · hit pre-market · 2 other WST headline(s) in the window, move may be shared
day 0 close · peak
-0.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Robert McMahon brings 34 years of experience in the healthcare industry.
  • His proven track record includes strong financial results and effective strategies.
  • The transition is expected to be seamless with Bernard Birkett's guidance.

Full Press Release Details

EXTON, Pa.,July 21, 2025/PRNewswire/ --West Pharmaceutical Services, Inc.(NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the appointment ofRobert McMahonas the company's new Chief Financial Officer (CFO), effectiveAugust 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition.
"Bob is an accomplished CFO and business executive within the healthcare industry who has guided several companies through dynamic environments and meaningful financial transformation during his impressive 34-year career. He brings a proven track record of delivering strong financial results, implementing effective financial and operational strategies, and demonstrating inspirational leadership," said Eric M. Green, President, Chief Executive Officer and Chair of the Board. "I'm pleased to welcome Bob to the West team and am confident that his expertise will be instrumental in helping steer our company forward and generating long-term shareholder value."
"Bob is an accomplished CFO and business executive within the healthcare industry who has guided several companies through dynamic environments and meaningful financial transformation during his impressive 34-year career. He brings a proven track record of delivering strong financial results, implementing effective financial and operational strategies, and demonstrating inspirational leadership," said Eric M. Green, President, Chief Executive Officer and Chair of the Board. "I'm pleased to welcome Bob to the West team and am confident that his expertise will be instrumental in helping steer our company forward and generating long-term shareholder value."
Mr. McMahon has been Chief Financial Officer of Agilent Technologies Inc. since 2018.  In this role, he is responsible for finance, audit, treasury, tax, investor relations, IT and procurement. Prior to Agilent, Mr. McMahon was the CFO at Hologic, Inc. and spent 20 years with Johnson & Johnson, in executive financial roles of increasing responsibility.  He has also served as an Independent Director at OraSure Technologies, Inc. since 2023.
"I'm excited by the opportunity to join such a well-positioned company with a talented team dedicated to improving patient health," said Mr. McMahon. "With a history of innovation spanning more than a century, I look forward to working alongside Eric and the leadership team to play a meaningful role in charting the next chapter of West's growth story for all stakeholders."

About WestWest Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.

Headquartered inExton, Pennsylvania, West in its fiscal year 2024 generated$2.89 billionin net sales. West is traded on the New York Stock Exchange (NYSE:WST) and is included on the Standard & Poor's 500 index. For more information, visitwww.westpharma.com.
All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.

Frequently Asked Questions

Who is the new CFO of West Pharmaceutical Services?

Robert McMahon has been appointed as the new Chief Financial Officer.

When will Robert McMahon start his role as CFO?

He will assume the role on August 4, 2025.

Who is Robert McMahon succeeding as CFO?

He is succeeding Bernard Birkett, who is retiring.

What is Robert McMahon's previous experience?

He was CFO at Agilent Technologies and has extensive experience in healthcare finance.

What are West Pharmaceutical Services' core operations?

They provide innovative injectable solutions and services for drug developers.

Last updated: Jul 21, 2025